about
Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatmentImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsThe urgent need to recover MHC class I in cancers for effective immunotherapySystems biology applied to vaccine and immunotherapy developmentReflections upon human cancer immune responsiveness to T cell-based therapyIssues in solid-organ transplantation in children: translational research from bench to bedside.An immunologic portrait of cancerInteraction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironmentApplications of translational bioinformatics in transplantationMelanoma NOS1 expression promotes dysfunctional IFN signalingMolecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma.Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyA systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection.Adaptive control of innate immunity.The stable traits of melanoma genetics: an alternate approach to target discoveryA multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.Monocyte-derived DC maturation strategies and related pathways: a transcriptional viewIdentification of common blood gene signatures for the diagnosis of renal and cardiac acute allograft rejectionTherapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of conceptGene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis.Tumor-Associated Glycans and Immune SurveillanceTGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor ImmunityGene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphomaA genetic inference on cancer immune responsivenessThe immunologic aspects of poxvirus oncolytic therapyNew take on comparative immunology: relevance to immunotherapy.Antitumor vaccines, immunotherapy and the immunological constant of rejectionGene-expression profiling in vaccine therapy and immunotherapy for cancerBottom up: a modular view of immunology.Radiation as an immunological adjuvant: current evidence on dose and fractionation.IRF5 gene polymorphisms in melanomaRegression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.Cooperativity of adaptive and innate immunity: implications for cancer therapy.Applying the uncertainty principle to immunology.Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients.Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.Transplantomics and biomarkers in organ transplantation: a report from the first international conference.
P2860
Q21328704-55C828F0-093C-4283-ADA0-B1366AD06096Q26765115-AFF523BD-2A05-43F0-8989-7C746E057C82Q26770165-C85B9FAD-DF78-4DE4-8A11-1CCFCA586BA9Q26830374-484D6B68-D01C-4E46-B3C8-0F03D6D4DAACQ27004674-395637E6-7F44-44CF-95AA-464F4AD08BF0Q27023312-8842FE68-B482-4326-8DF0-330A48341E78Q27028000-59197DE2-F3AD-442A-A89F-0F7AA7F33218Q28389479-7CAC1503-9150-4798-901E-DC93BEFC7124Q28716539-2B2484DF-BEE1-4226-A287-4FAA8FDF67F4Q30413226-1220B185-765B-4B0D-8153-A54B381C13C0Q30423599-E0E23142-4A37-46D9-8599-796257E93F24Q30438965-87647DE0-F7A6-4D92-A66D-DBA3D87C9C9AQ30440347-901F6156-02DE-467E-87C2-9A1D84C11448Q33479314-DBDB33A0-7F60-4378-A8EE-269C5BEFBF45Q33750137-114F4D86-4F24-4167-93A7-6E230DC4942DQ33820196-4D231F0C-BA19-4ED5-9CF8-312A687B5AA1Q33912853-2E05D019-F8C5-4B8F-95D0-60DB1C3CAF15Q34248355-81A2612A-22F1-4EB3-AAA6-62A00D263CDCQ34387506-0F0D869D-2EFC-4930-9602-AAEDEC77B6C6Q34916497-B95F20E6-3584-4454-8C9D-F4144B04C26BQ35072635-8441E9C9-8E07-42AE-903C-F5A6CAB32413Q35193892-2A2C1819-6407-475D-9869-69CD86F01B2EQ35541507-2437CDC5-30F2-4D6F-8903-81A339F1C430Q35890610-B35DE275-B298-4CA6-BBA0-D0F684A8DFA6Q35908369-17E2A000-9333-4C3C-9459-E4B7FEB25670Q36051184-8F4B585F-7C69-4C09-A943-D69E432AD2AFQ36057497-E396EB29-8E3A-4CEA-8D8D-78D03F3225D2Q36115128-16F8A493-D3FB-418F-A8A1-4AD8FD2B9A8FQ36126352-939CDBA3-6B01-46C4-8672-4C7BD2D4D6C2Q36136498-665A971D-B106-457E-8976-C1589EA3FA22Q36138329-EE46A47D-9102-4104-9A0F-6414FF4026D0Q36158286-2AAD9F1C-E7BF-412D-AAF8-0B19B7543C76Q36347177-95489B0C-03F1-41F3-9027-8D4A60F992FAQ36380375-E43045C4-A5A5-4C8E-A5A1-6698C3D4D8A0Q36419244-837F6755-E01C-452A-8C5E-26BE13CB2940Q36429508-3B33D27D-3231-459D-A577-4D90BE10D1B8Q36453221-FD3BFB7C-8343-4061-81C4-3B974312252CQ36960012-2B7D12BB-57DD-437D-8091-9087886B4B77Q37059747-DDB4851A-A32A-43B4-ACD5-AB1DD0776602Q37146013-B6E63CB9-509F-4094-94D7-82595E0800BB
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The immunologic constant of rejection.
@en
The immunologic constant of rejection.
@nl
type
label
The immunologic constant of rejection.
@en
The immunologic constant of rejection.
@nl
prefLabel
The immunologic constant of rejection.
@en
The immunologic constant of rejection.
@nl
P2093
P356
P1433
P1476
The immunologic constant of rejection.
@en
P2093
Andrea Worschech
Francesco M Marincola
P304
P356
10.1016/J.IT.2008.03.002
P577
2008-05-03T00:00:00Z